Showing 20 of 200 recruiting trials for “large-granular-lymphocyte-leukemia”
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
👨⚕️ Jianxiang Wang, Dr., Institute of Hematology & Blood Diseases Hospital, China📍 11 sites📅 Started Dec 2020View details ↗
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
👨⚕️ Natalie Grover, MD, UNC Lineberger Comprehensive Cancer Center📍 1 site📅 Started Nov 2020View details ↗
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingNCT04290000 ↗
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
👨⚕️ Christine E Gruessner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Jun 2019View details ↗
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
👨⚕️ Matthew J Wieduwilt, Alliance for Clinical Trials in Oncology📍 271 sites📅 Started May 2019View details ↗
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
👨⚕️ Prof. Dr. Michael Schmitt, University Hospital Heidelberg, Department V📍 2 sites📅 Started Sep 2018View details ↗
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →